USPTO Examiner GEMBEH SHIRLEY V - Art Unit 1615

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19005284DRUG POWDERIZATION WITHIN VIALSDecember 2024June 2025Allow610NoNo
18977541COMPOSITIONS AND COMPOUNDS CONTAINNG BETA-HYDROXYBUTYRATE AND ONE OR MORE AMINO ACIDSDecember 2024March 2025Allow300YesNo
18744999Roflumilast Formulations with an Improved Pharmacokinetic ProfileJune 2024November 2024Allow510NoNo
18670960METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSMay 2024June 2025Allow1310NoNo
18665222SELENIUM DISULFIDE COMPOSITIONS FOR USE IN TREATING MEIBOMIAN GLAND DYSFUNCTIONMay 2024June 2025Allow1430YesNo
18662430METHOD OF IMPROVING FLAVOR OF A COMPOSITION OF (D)-BETA-HYDROXYBUTYRIC ACID AND (D)-1,3 BUTANEDIOL AND USE AS A NUTRITIONAL SUPPLEMENT AND THERAPEUTIC AGENTMay 2024June 2025Allow1310NoNo
18652380METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS OF PREPARING THE SAMEMay 2024June 2025Allow1410NoNo
18631405TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVEApril 2024March 2025Allow1120NoNo
18606903ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDSMarch 2024August 2024Allow510NoNo
18606925ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDSMarch 2024August 2024Allow510NoNo
18606946ARYL-OR HETEROARYL-SUBSTITUTED BENZENE COMPOUNDSMarch 2024August 2024Allow510NoNo
18598377ACID/ANIONIC ANTIMICROBIAL AND VIRUCIDAL COMPOSITIONS AND USES THEREOFMarch 2024April 2025Allow1320NoNo
18597574Roflumilast Formulations with an Improved Pharmacokinetic ProfileMarch 2024May 2024Allow200YesNo
185959853, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USEMarch 2024January 2025Allow1110NoNo
18591994ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANSFebruary 2024July 2024Allow510NoNo
18425676PHARMACEUTICAL AEROSOL PRODUCT FOR ADMINISTRATION BY ORAL OR NASAL INHALATIONJanuary 2024March 2025Allow1410NoNo
18418799PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETOJanuary 2024March 2025Allow1410NoNo
18541675METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCERDecember 2023January 2025Allow1310NoNo
18535124BODY FLUID RESISTANT TISSUE ADHESIVESDecember 2023January 2025Allow1400NoNo
18535764METHODS OF REDUCING MAMMOGRAPHIC BREAST DENSITY AND/OR BREAST CANCER RISKDecember 2023April 2025Allow1610YesNo
18531229METHODS OF ADMINISTERING ANTI-EPILEPSY AGENTS AND TRANSPORT INHIBITORS TO A SUBJECTDecember 2023January 2025Allow1410YesNo
18503967METHODS FOR THE USE OF 5'-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)November 2023April 2025Allow1710NoNo
18371071METHODS FOR TREATING ANTIPSYCHOTIC-INDUCED WEIGHT GAINSeptember 2023September 2024Allow1200YesNo
18367405METHOD OF TREATING CARDIOVASCULAR EVENTS USING COLCHICINE CONCURRENTLY WITH AN ANTIPLATELET AGENT AND STATINSeptember 2023October 2024Allow1310NoNo
18367412TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVESeptember 2023October 2024Allow1320YesNo
18240406NALOXONE FORMULATIONS FOR SUBLINGUAL AND/OR BUCCAL ADMINISTRATIONAugust 2023January 2025Allow1710NoNo
18365406METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE MINIMIZING SIDE EFFECTSAugust 2023April 2025Abandon2110NoNo
18353870METHOD FOR REDUCING SIDE EFFECTS FROM ADMINISTRATION OF PHOSPHODIESTERASE-4 INHIBITORSJuly 2023March 2024Allow810NoNo
18219556ADMINISTRATION OF R-BETA-HYDROXYBUTYRATE AND RELATED COMPOUNDS IN HUMANSJuly 2023December 2024Allow1700YesNo
18219090ANTIMICROBIAL AND ANTI-INFLAMMATORY COMPOSITIONSJuly 2023January 2025Allow1810YesNo
18219526COVID-19 BINDING AEROSOLSJuly 2023January 2024Allow620NoNo
18219009COVID-19 BINDING AEROSOLSJuly 2023September 2023Allow200NoNo
18214019Method of Treating or Preventing Alzheimers DiseaseJune 2023October 2023Allow410NoNo
18207931BEADED TOBACCO MATERIAL AND RELATED METHOD OF MANUFACTUREJune 2023September 2024Allow1510NoNo
18331875METHOD OF ADMINISTRATION AND TREATMENTJune 2023January 2025Allow2020NoNo
18319355Biomarkers For Neurodegenerative DiseaseMay 2023September 2024Allow1620YesNo
18144470TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVEMay 2023November 2023Allow710NoNo
18144528TREATMENT OR PREVENTION OF CARDIOVASCULAR EVENTS VIA THE ADMINISTRATION OF A COLCHICINE DERIVATIVEMay 2023December 2023Allow710YesNo
18132480Compositions and Methods of Treating Cardiac Fibrosis with IfetrobanApril 2023August 2024Allow1610NoNo
18130141DRUG POWDERIZATION WITHIN VIALSApril 2023October 2024Abandon1910NoNo
18122812SOFT GEL CAPSULE PREPARATIONSMarch 2023August 2023Allow501YesNo
18184562EXPLOITING OXYGEN INHIBITED PHOTOPOLYMERIZATION WITHIN EMULSION DROPLETS FOR THE FABRICATION OF MICROPARTICLES WITH CUSTOMIZABLE SIZE, SHAPE AND INTERFACIAL AND MECHANICAL PROPERTIESMarch 2023September 2024Allow1810NoNo
18121162MOIST ORAL COMPOSITIONSMarch 2023April 2024Allow1300YesNo
18120305COVID-19 BINDING AEROSOLSMarch 2023September 2023Allow611NoNo
18104530MULTIDRUG PAIN MANAGEMENT PACKAGEFebruary 2023October 2024Allow2110NoNo
18157302METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDEJanuary 2023October 2024Allow2110NoNo
18152240METHODS OF TREATING CHRONIC WOUNDS USING ELECTROSPUN FIBERSJanuary 2023September 2024Allow2010NoNo
18149916HAIR GROWTH COMPOSITION AND METHOD FOR MAKING AND USING THE SAMEJanuary 2023May 2025Allow2800NoNo
18065368STABILIZED FORMULATIONS OF LIPID NANOPARTICLESDecember 2022July 2024Allow1910NoNo
18064396RUBBER-BASED SOFT GEL SKIN ADHESIVESDecember 2022July 2024Allow1910NoNo
17987095TREATMENT OF DIABETES MELLITUSNovember 2022July 2024Allow2010YesNo
17980827AMORPHOUS FORM OF TETRACYCLIC COMPOUNDNovember 2022October 2024Abandon2310NoNo
17973691COMPOSITIONS AND METHODS FOR LONG LASTING DISINFECTIONOctober 2022October 2024Abandon2310NoNo
17921141PHARMACEUTICAL COMPOSITIONS AND USES THEREOF IN TREATING PARKINSON'S DISEASEOctober 2022April 2025Allow2900YesNo
17965220DRUG-LOADED MESOPOROUS SILICA NANOPARTICLE FOR PREVENTION AND TREATMENT OF BRAIN CANCERS OR BRAIN METASTASESOctober 2022December 2024Allow2621YesNo
17959091AN INSTANT UNDERWATER BIO-ADHESIVE CONTAINING CATECHOL MOIETIES AND WATER-RESISTANT CHOLESTEROLOctober 2022October 2024Allow2511YesNo
17936385EXTRACELLULAR MATRIX-BASED BIOADHESIVESeptember 2022April 2025Allow3031YesNo
17898632Crenolanib for Treating FLT3 Mutated Proliferative DisordersAugust 2022September 2024Allow2410NoNo
17882391NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMINAugust 2022June 2024Allow2310YesNo
17873800NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMINJuly 2022June 2024Allow2310NoNo
17869145NEUROACTIVE STEROID FORMULATIONS AND METHODS OF TREATING CNS DISORDERSJuly 2022August 2024Abandon2510NoNo
17813055METOLAZONE EMULSION FORMULATIONJuly 2022June 2024Allow2311NoNo
17867495NEUTRAL PH COMPOSITIONS OF DOCETAXEL AND HUMAN SERUM ALBUMINJuly 2022June 2024Allow2310YesNo
17838534DELIVERY OF LIQUID COMPOSITION AND OXYGENJune 2022April 2024Abandon2220NoNo
17836854MOIST ORAL COMPOSITIONSJune 2022June 2025Allow3610NoNo
17836836COMBINATION THERAPIES AND METHODS OF USE THEREOF FOR TREATING CANCERJune 2022May 2024Allow2310NoNo
17836692ORAL COMPOSITION WITH BEET MATERIALJune 2022June 2025Allow3610NoNo
17836790ORAL COMPOSITIONS WITH REDUCED WATER ACTIVITYJune 2022June 2025Allow3610YesNo
17743654METHOD FOR PREPARING MODIFIED STARCH, LIPOSOME AND METHOD FOR PREPARING LIPOSOMEMay 2022May 2024Allow2421YesNo
17739401USE OF CDK9 INHIBITORS TO REDUCE CARTILAGE DEGRADATIONMay 2022November 2024Abandon3020YesNo
17738636Highly Elastic Medical Sealants for Flexible Soft TissueMay 2022August 2024Allow2721NoYes
17738801Nutraceutical Composition Comprising a Water-Soluble Fullerene and a KetoneMay 2022August 2024Allow2721YesNo
17737725Methods Of Treating Dyskinesia And Related DisordersMay 2022March 2024Allow2210YesNo
17774099USE OF IODIDE COMPOUNDS FOR THE TREATMENT AND PREVENTION OF CHEMOTHERAPY-ASSOCIATED CACHEXIA AND CARDIOTOXICITYMay 2022June 2025Abandon3810NoNo
17734796DELIVERY SYSTEMS BASED ON HYDROGEL COMPOSITIONS AND METHODS THEREOFMay 2022November 2023Allow1800NoNo
17712601Nanofiber Structures and Methods of Use ThereofApril 2022February 2024Allow2211NoNo
17712302SOFT GEL COMPOSITIONS AND CAPSULES MADE FROM THE SAMEApril 2022March 2024Allow2310YesNo
17765953HYDROPHOBICALLY-MODIFIED BIOPOLYMER MATERIALSApril 2022September 2024Allow2910YesNo
17703238THERMOSENSITIVE BIO-ADHESIVE HYDROGEL FOR REMOVAL OF URETERAL AND RENAL STONESMarch 2022October 2022Allow710NoNo
17761455COSMETICMarch 2022January 2025Allow3410YesNo
17695687Metal Oxide Encapsulated Drug Compositions and Methods of Preparing the SameMarch 2022February 2024Allow2310YesNo
17642129ADDITIVE COMPOSITION FOR PREVENTING VITAMIN C PRECIPITATIONMarch 2022June 2025Allow3920NoNo
17689666Compositions and Methods for the Treatment of Amyotrophic Lateral Sclerosis, Parkinson's Disease, Parkinson's Disease with Dementia, Dementia with Lewy Bodies, and Multiple System AtrophyMarch 2022February 2024Allow2310NoNo
17639454METHODS OF TRAPPING CRUSTACEANSMarch 2022January 2025Allow3510NoNo
17679682Highly Soluble Rebaudioside DFebruary 2022December 2023Allow2210NoNo
17678672NUTRITIONAL COMPOSITION AND INFANT FORMULA FOR PROMOTING DE NOVO MYELINATIONFebruary 2022January 2024Allow2310NoNo
175913063, 7-DIAMINO-10H-PHENOTHIAZINE SALTS AND THEIR USEFebruary 2022December 2023Allow2210NoNo
17631980BIOCIDAL DISPERSIONS FOR COATING COMPOSITIONSFebruary 2022May 2025Abandon3901NoNo
17631659Feed Stuff for Beneficial Organisms that can be used in Integrated Pest ManagementJanuary 2022March 2025Allow3710YesNo
17583870BIOLOGICAL TRANSPLANTATION MATERIALJanuary 2022April 2025Abandon3810NoNo
17579981PDE5 INHIBITOR POWDER FORMULATIONS AND METHODS RELATING THERETOJanuary 2022June 2023Allow1720YesYes
17628400COSMETIC COMPOSITION COMPRISING AN ORAL CAPSULE CONTAINING HYALURONIC ACID AND WHEAT GRAIN OIL WITH PHYTOCERAMIDESJanuary 2022May 2025Abandon4010NoNo
17577882METHODS AND COMPOSITIONS RELATED TO GLUCOCORTICOID RECEPTOR ANTAGONISTS AND BREAST CANCERJanuary 2022October 2023Allow2110NoNo
17440061METHOD FOR COATING INSOLUBLE SOLIDSJanuary 2022January 2025Allow4020YesNo
17625964POLYURETHANE GELSJanuary 2022June 2025Allow4121YesNo
17625474HAIR COSMETICJanuary 2022March 2025Allow3810NoNo
17570683Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using SameJanuary 2022June 2022Allow510NoNo
17562787METHOD OF ADMINISTRATION OF GAMMA HYDROXYBUTYRATE WITH MONOCARBOXYLATE TRANSPORTERSDecember 2021January 2024Allow2510NoNo
17559074FATTY ACID AMIDES AND USES THEREOF IN THE TREATMENT OF NAUSEADecember 2021May 2025Abandon4110NoNo
17558195USE OF GABOXADOL, GANAXOLONE AND ALLOPREGNANOLONE TO TREAT MOVEMENT DISORDERSDecember 2021September 2024Abandon3220NoYes

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GEMBEH, SHIRLEY V.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
19
Examiner Affirmed
13
(68.4%)
Examiner Reversed
6
(31.6%)
Reversal Percentile
47.4%
Lower than average

What This Means

With a 31.6% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
58
Allowed After Appeal Filing
17
(29.3%)
Not Allowed After Appeal Filing
41
(70.7%)
Filing Benefit Percentile
41.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 29.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GEMBEH, SHIRLEY V - Prosecution Strategy Guide

Executive Summary

Examiner GEMBEH, SHIRLEY V works in Art Unit 1615 and has examined 703 patent applications in our dataset. With an allowance rate of 76.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 23 months.

Allowance Patterns

Examiner GEMBEH, SHIRLEY V's allowance rate of 76.8% places them in the 35% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.

Office Action Patterns

On average, applications examined by GEMBEH, SHIRLEY V receive 1.66 office actions before reaching final disposition. This places the examiner in the 46% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GEMBEH, SHIRLEY V is 23 months. This places the examiner in the 74% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +26.4% benefit to allowance rate for applications examined by GEMBEH, SHIRLEY V. This interview benefit is in the 77% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.2% of applications are subsequently allowed. This success rate is in the 55% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 43.9% of cases where such amendments are filed. This entry rate is in the 61% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 73.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 58% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 63.5% of appeals filed. This is in the 37% percentile among all examiners. Of these withdrawals, 42.4% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 44.8% are granted (fully or in part). This grant rate is in the 49% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 1.0% of allowed cases (in the 68% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.4% of allowed cases (in the 47% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.